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ABSTRACT 
Objective: The present study was an attempt to systemically deliver the most desirable schizophrenia drug, ziprasidone hydrochloride (ZRS) via 
the intranasal route using nanostructured lipid carrier (NLC) approach.  
Methods: The desired ZRS loaded NLCs were developed using central composite statistical design and the developed formulation was monitored 
for improving ZRS bioavailability and their brain targeting efficacy.  
Results: Pharmacokinetic studies revealed a 10 fold increase (ZRS blood-brain ratio) for NLCs administered through nasal route (in comparison to 
intravenous route). Similarly, the concentration of ZRS (in the brain) delivered via nasal route exhibits 4 fold increment at all-time points.  
Conclusion: Therefore, the obtained results suggest a potential nose to brain transport of loaded ZRS by effective bypassing of the Blood-Brain Barrier 
(BBB). 
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Schizophrenia is considered a chronic health disorder pertaining to 
mental issues, which can be diagnosed by a range of symptoms like 
hallucinations, disorientation in both behavior and speech, cognitive 
impairment and delusive behavior. Further, due to its chronic nature 
and early-onset schizophrenia is considered as disabling disorder 
(due to negative and cognitive symptoms) both for patients and 
their people [1, 2]. Additionally, due to positive symptoms 
(hallucinations, delusional behavior and suspiciousness), there is a 
chance of relapse even after receiving treatment. Finally, due to its 
characteristic heterogeneousness, there is a lack of understanding 
regarding various aspects of this disorder [3]. Nevertheless, 
systemic drug delivery to treat schizophrenia is a potential 
challenge, owing to Blood-Brain Barrier (BBB) effects, which often 
obstruct the efficient transport of a rational drug (to the brain) [4]. 
Techniques employed to deliver drugs to the brain by by-passing blood-
brain-barrier are categorized as invasive and non-invasive methods. 
Wherein, delivering drugs through invasive route was not always 
welcomed by the patient since it causes irreversible damage to barrier 
integrity which leads to severe adverse effects like changes in 
neuropathological functioning and enhanced contact to toxic molecules. 
Further, non-invasive delivery of drugs aids direct transport of drugs 
into the brain by evading surgical intrusions [5, 6]. In the modern era 
nose has been considered as a route of delivery for both local and 
systemic effects. In the last two decades, there are more advances in 
large scale production of drugs especially proteins and peptides [6]. 
 Nasal cavity possesses a great expanse which affords potential 
alternative for brain delivery by avoiding first-pass metabolism and 
invasiveness and swift oncoming, simultaneously increasing the patient 
ease and compliance. Additionally, the nasal cavity acts as a barrier to 
transport moieties with high molecular weights like peptides. Further, 
this hurdle can be overcome by employing permeation enhancers in the 
formulations which in turn opens up the tight joints of the barrier for 
paracellular transport of the selected moieties. Nasal delivery also owns 
other advantages like trouble-free administration and self-medication is 
possible during critical conditions [7]. 
Since the beginning of the 20th
In the current study, a second-generation, atypical antipsychotic 
drug Ziprasidone hydrochloride (ZRS) is selected. Further, it has a 
half-life of 7 h and requires repeated dosage (i.e. 20-100 mg per day) 
with poor oral bioavailability. Additionally, the said drug also suffers 
from extensive first-pass metabolism, low absorption and very low 
drug concentration reach the brain, especially during oral 
administration [12]. Thus, herein, we intend to establish the ZRS 
delivery efficacy (to the brain) via NLC based nasal route, which may 
aid in enhancing permeation and bioavailability and thereby act as 
an effective approach towards systemic drug delivery.  
 century, nanotechnology growing 
interested in pharmaceutical technology research groups 
worldwide. Further, excipients used in this nanoformulations are 
generally biocompatible and degradable, so that drugs can be 
delivered at the required site of action with the controlled release by 
reducing the toxicity [8]. The method of complete crystallization or 
recrystallization of fat present in the formulation reduces the 
solubility of the loaded drug, thereby leading to expulsion of the 
drug from the formulation especially in lipid nanoparticles. 
Additionally, most of the lipophilic drugs are highly soluble in a 
liquid lipid when compared with a solid lipid. Thus, NLC is an 
updated version for solid lipid nanoparticles (SLN), where both solid 
and liquid lipids were present in the oil phase are increasingly 
preferred over SLN, as it overcomes major disadvantages of SLN, 
such as low drug loading and drug expulsion related issues [9-11]. 
MATERIALS AND METHODS 
Materials  
Ziprasidone hydrochloride was obtained as a gift sample from 
Jubilant Generics Ltd (Mysuru, India). While, Gelucire 43/01 and 
44/14, was gifted by Gattefosse (France). Further, Capmul MCM, 
Captex 200, Cremophor EL, Sterotex FL were also obtained as a gift 
sample from Abitec Group, (USA). However, Span 80, PEG 400 and 
Oleic acid were purchased from Merck (Mumbai, India). While, 
Tween 80, Tween 20 and polyvinyl alcohol (PVA) were purchased 
from Loba Chemie Pvt. Ltd., (Mumbai, India).  
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Methods 
Solubility studies  
In order to handpick the best suitable excipients towards 
formulating desired NLC, the solubility of ZRS in various lipids 
was ascertained. In a typical experiment, an excess amount of 
selected drug was mixed with selected liquid lipids with the aid 
of vortex mixer. The obtained mixtures were set aside for 72h 
and followed by centrifugation for 10 min at 5,000 rpm. Further, 
0.5 ml of supernatant was drawn from the obtained solutions 
and analyzed using electronic spectral studies at 315 nm 
(UV1800, Shimadzu, Japan). Additionally, for solid lipids, the 
minimum amount of molten lipids required to solubilize the 
desired drug was quantified via visual observation wherein the 
formation of a clear solution of melted lipids with ZRS was 
considered the endpoint [13]. 
Compatibility studies  
Differential scanning calorimetry (DSC) thermogram was 
obtained with Shimadzu DSC-60 calorimeter over a temperature 
range of 40 to 300 °C and at a constant heating rate of 20 °C/min 
[14]. 
Pseudo ternary phase diagrams construction 
Phase diagrams which are essential in optimizing the Smix ratio were 
constructed using aqueous titration technique. Wherein, the selected oil 
phase was heated and maintained at a temperature of 75 °C, to which 
selected Smix was added in varying ratios (1:9, 2:8,3:7, 4:6, 5:5, 6:4, 7:3, 
8:2 and 9:1) so as to form homogeneous mixtures. The mixtures so 
obtained were then titrated against the desired aqueous phase, and the 
changes observed were recorded visually [15]. 
Effect of process/formulation variables 
Effect of the liquid component 
To analyze the influence of oil phase over the desired NLC’s particle 
size, different batches of NLC were formulated with varying oil 
phase concentrations (1%, 2%, and 3%) by keeping the Smix ratio 
constant at 2:1 for ZRS. Selected oil phase and Smix ratios were 
weighed and transferred into glass vials.  
Further, the samples were mixed by using a vortex mixer and heated 
at a temperature of 70 °C to form a homogenous mixture [16]. 
Particle sizes were identified visually by using the following grade 
system table 1. 
  
Table 1: Grading system for visual determination of particle size 
S. No. Appearance of dissolution medium Particle size range Grade 
1 Transparent 10 nm–200 nm MEa 
2 Translucent 200 nm–300 nm ME
3 
b 
Fine milky 300 nm–few μm E 
4 Presence of particles Depends on the API NE 
MEa:  E: Emulsion Grade A, clear microemulsion 
 MEb: NE: No emulsion Grade B, microemulsion 
 
Effect of the solid component  
To study the effect of solid lipid concentration on the 
formulation of desired NLCs was done by preparing NLCs by 
varying solid lipid ratio to liquid lipid i.e. 1:1, 1:2, 1:3. Where 
briefly 500 mg of lipid phase was added to water and agitated 
gently with the aid of magnetic stirrer and the obtained blends 
were accessed visually for clear, turbid and presence of lumps in 
the solution [16].  
Formulation of NLCs containing ZRS 
The desired NLC formulations were prepared using hot 
homogenization, followed by rapid ultra-sonication, wherein selected 
quantity of desired drugs were dissolved in molten lipids and 
simultaneously, aqueous phase consisting of all other components 
were heated separately at a constant temperature. Post drug 
dissolution obtained blend was transferred to aqueous medium with 
vigorous stirring for 5 min at 10,000 rpm with a hot homogenization 
((Polytron® PT1600E). Further, a probe sonicator was used to 
sonicate the obtained emulsion and desired NLC was stored in amber-
colored glass vials at a temperature of 2-10 °C. Additionally, to 
demonstrate the response surface model, Design expert software 
(Version 11, Stat-Ease Inc., and Minneapolis, U. S. A.) was employed. 
Central composite design (CCD) is used to form a second-order 
quadratic equation without using a complete three-level factorial 
experiment. A 2 factor, 2 levels central composite design was used to 
design the optimized procedure to formulate the desired ZRS-NLC. 
Wherein Oil phase and Smix were selected as independent variables 
and drug loading, entrapment efficiency, and particle size were 
considered as dependent variables. This leads to a process of 
optimization with a small experimental design (13 runs) [17].  
Evaluation of ZRS-NLCs 
Drug loading and encapsulation efficiency  
The amount of ZRS loaded in relation to the lipid phase and its 
encapsulation efficiency was determined by centrifuging (REMI 
laboratory Instrument, India) a fixed volume of desired NLC for 20 min 
at 10000 rpm. The supernatant so obtained was diluted appropriately 
and the amount of ZRS loaded and encapsulation efficiency was 
quantified using UV spectrophotometric measurements at 315 nm 
(UV1800, Shimadzu, Japan) [18], using the following equations;  
Drug Loading (DL) (%) = (Wd−Ws
Wn
) ∗ 100 (1) 
Entrapment efficiency (EE) (%) = (Wd−Ws
Wd
) ∗ 100 (2) 
Where Wd is the total weight of the drug is taken, Ws is the weight of 
the drug in the supernatant and Wn
Particle size  
 is the total weight of obtained 
NLC. 
Dynamic light scattering technique was used to estimate 
parameters (particle size and polydispersity index) of the 
formulated drug-loaded NLCs by using a particle size analyzer 
(Model Zetasizer Nano ZS, Malvern Ltd., UK) at a scattering angle 
of 90 ° [19]. 
Surface morphology  
The surface morphology of ZRS-NLC was recorded using a (Hitachi 
Noran System 7 scanning electron microscope (SEM), USA) [20]. 
In vitro drug release studies in optimized ZRS loaded NLC 
The drug release studies for ZRS-NLC were accomplished using the 
dialysis membrane (Hi-media, Mumbai, India). In a typical 
experimental set-up, NLC equivalent to 100 mg of the selected drug 
was measured and placed on the dialysis membrane. The bag so 
formed, was placed in beaker containing a fixed quantity of 
simulated nasal fluid (SNF) (pH 6.4) i.e. 250 ml maintained at a 
temperature of 37 ° C. From which, samplings were carried out at 
predetermined intervals, during which 2 ml of aliquots were 
repeatedly withdrawn from the receptor compartment and 
replenished with fresh buffer. Finally, the amount of ZRS released 
was quantified spectrophotometrically at 315 nm (UV1800, 
Shimadzu, Japan) [21]. 
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Ex vivo diffusion studies of optimized ZRS-NLCs  
Ex-vivo permeation studies for both pure drug and drug-loaded NLCs 
were performed by using sheep nasal mucosa. Excised sheep nasal 
mucosa was obtained from a local butchery house followed by 
washing with PBS solution and isopropyl alcohol. In order to place 
the samples on donor and receptor components of diffusion cell, 
obtained nasal mucosa was sliced into small pieces with a thickness 
of 0.2 mm. The mounted samples were finally stabilized using PBS 
treatment for 15 min at a temperature of 39±0.5 °C. The resulting 
sample was then mounted on a rim of the receptor compartment 
with freshly filled dissolution media and the donor compartment 
was placed over it. Finally, the samples were considerately drawn 
from the respective compartments and analyzed for the amount of 
ZRS permeated across the tissue using UV absorbance studies at 315 
nm [22]. 
Nasal ciliotoxicity studies 
The nasal ciliotoxicity studies were performed with freshly isolated 
sheep mucosa, where each tissue sample was treated with isopropyl 
alcohol (IPA) (positive control), optimized NLCs (the formulation 
understudy) and PBS (negative control). The tissue samples so 
processed were stored in 10% formalin solution for 2 h, followed by 
H and E staining for histopathological imaging [23]. 
In vitro haemolytic toxicity study 
In order to estimate the in vitro toxicity and in vivo membrane damage, 
haemolytic toxicity study has to be conducted. Wherein, blood from 
sheep was collected in a vial coated with Ethylene Diamine Tetra 
Acetic Acid (EDTA) which acts as an anti-coagulant. Further, Red blood 
cells were separated by centrifugation followed by filtration. The 
absorbances of the obtained solutions (5-500 µg/ml) were then 
determined at 315 nm by using UV spectrophotometer. In this study 
Trition X 100 is used as positive control and buffer is used as a 
negative control [24] and the following equation was used to calculate 
% of lysis for each concentration.  
%Haemolysis = Absorbance of Test−Absorbance at 0%
Absorbance at 100% lysis−Absorbance at 0%
∗ 100…………… (3) 
In vivo bio-distribution studies 
The study was conducted after obtaining approval (No. 
155/PO/Re/S/99/CPCSEA) from JSS College of Pharmacy, Mysuru 
institutional animal ethical committee. Rats (Wister albino) 
weighing 180-200g were selected for bio-distribution studies, as per 
the guidelines set by The National Institutes of Health, all the 
animals were humanely treated. In order to perform bio-distribution 
studies, selected rats were divided into two groups. Wherein, one 
group received intranasal formulations, while the other received a 
dose which is equivalent to 2.3 mg/kg body weight intravenously via 
injection through the tail vein. Nevertheless, for intranasal 
administration, a 50 µl dose was administered by holding the rats 
from back in slanted position from the formulation, which is 
equivalent to 6 mg/ml [25]. 
Pharmacokinetic and brain distribution study  
The plasma and brain samples required for pharmacokinetic and 
brain distribution studies were collected by suitably anesthetizing 
the animals, before scarification. The typical plasma and brain 
sample collections involved drawing of 2 ml of blood at different 
time intervals by employing cardiac puncture technique and the 
obtained blood samples were stored in EDTA tubes under cold 
conditions. However, for plasma separation, centrifugation was done 
for 15 min at 5000 rpm for the drawn blood samples. Further, 
obtained plasma was mixed with internal standard and 2 ml of 
acetonitrile was added to bring about protein precipitation. Post-
precipitation, the plasma samples were further thoroughly mixed 
and centrifuged for a short period of time (5 min at 4000rpm). To 
finish, supernatant obtained from the centrifuged solutions was 
collected and prior to analysis the obtained samples were dried at 
ambient temperatures and reconstituted with the selected mobile 
phase and filtered through a membrane filter.  
Post blood collection, animals were decapitated immediately and the 
skull was slit to excise the brain carefully. In order to get free from 
attached blood vessels, the obtained brain tissue was quickly 
washed with saline water and marked with the help of a filter paper 
and stored in PBS. The stored tissues were then homogenized for 1 
min at 10000 rpm followed by centrifugation and the obtained 
samples were analyzed by using HPLC. Post analysis of various 
pharmacokinetic parameters was calculated by using formulas that 
were cited elsewhere [26]. 
RESULTS AND DISCUSSION 
Solubility studies  
The selection of right excipient towards the effective formulation of 
NLC is mostly dependent on the solubility of the desired drug (in 
actual excipients). Accordingly, data obtained from solubility studies 
of ZRS in various components were depicted in fig. 1-2. All the 
excipients chosen had shown a better solubility for ZRS. While, the 
initial selection of lipids few liquid lipids were obtained and 
solubility of ZRS was ascertained in the same (fig. 1), from the 
results obtained it was evident that Capmul MCM had shown 
maximum solubility of ZRS and was selected as a liquid lipid to 
formulate the desired NLCs.  
Quantity of the obtained solid lipids required to solubilize 20 mg of ZRS 
was calculated and depicted in fig. 2. From the results, it was evident that 
Gelucire 43/01 had shown a better solubility when compared with other 
lipids. Further, results also suggested that ZRS had shown more 
solubility in liquid lipids when compared with solid lipids. Additionally, it 
was found that Gelucire 43/01 had formed a homogeneous mixture 
when combined with Capmul MCM without any phase separation for 
24h, suggesting that the selected liquid lipid has completely entrapped in 
solid lipid which is the initial step in formulating the desired NLCs. On 
basing these solubility studies Capmul MCM and Gelucire 43/01 were 
selected as the lipid phase for further studies [13]. 
  
 
Fig. 1: The solubility of ZRS in liquid lipids; mean±SD, n=3 
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Thermograms obtained from DSC analysis for both pure ZRS and ZRS 
physical mixture were depicted in fig. 3 respectively. Wherein, pure 
ZRS thermogram had shown a sharp endotherm peak at 236.68 °C, 
which is in agreement with ZRS’s melting range. While, the physical 
mixture displayed two peaks, first at 39.28 °C (corresponding to the 
oil phase), where the drug may be molecularly dispersed in 
corresponding lipids. While, the second peak at 237.48 °C may be 
attributed to pure ZRS, indicating the absence of undesirable drug-
lipid interactions [27]. 
  
 
Fig. 3: DSC thermogram of ZRS and physical mixture 
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Construction of pseudo-ternary phase diagrams 
The (drug excipient) formulations, which remained as nanoemulsions 
(when dispersed) were subjected to further studies. Nanoemulsions 
composed of oil phase (Capmul MCM and Gelucire 43/01), Labrasol as 
surfactant and Transcutol-p as co-surfactant, which were selected for 
further optimization. As can be seen from fig. 4(A-D)-5(A-D), the 
nanoemulsion formation area increases with an increase in the Smix 
ratio and found to be highest at 2:1. Consequently, 2:1 Smix ratio was 
maintained for further optimizations [28]. 
  
 
Fig. 4 (A-D): Pseudo-ternary phase diagram for a group I 
 
 
Fig. 5 (A-D): Pseudo-ternary phase diagram for group II 
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Effect of process/formulation variables 
Effect of liquid lipid concentration 
When the concentration of the oil phase is increased above 1% there 
was a substantial enhancement in particle size. Obtained results 
suggested that an increase in the ratio of oil phase to Smix has 
increased particle size. Therefore, 1% of lipid concentration was 
considered as optimum concentration for further batches (table 2). 
Effect of the amount of solid lipid on ease of emulsification 
Obtained results revealed that formulation consisting of 1:1 ratio of 
lipid phase has produced translucent solutions, while 1:2 and 1:3 
formulations had shown milky and turbid appearance as depicted in 
table 3. An increase in the solid lipid content has increased 
emulsification time, which is due to the melting point of Gelucire 
43/01. An increase in the weight ratio of solid lipids led to globules 
with increased size. Therefore, to achieve rapid dissolution rates, 1:1 
lipid ratio was selected for further development of NLC. 
 
Table 2: Effect of liquid lipid concentration 
S. No. Concentration (µg/ml) Visual reading Result 
1 1% Translucent MEa 
3 2% Fine milky E 
3 3% Fine milky E 
 
Table 3: Effect of solid lipid on ease of emulsification 
S. No. Oil: solid lipid Visual reading Result 
1 1:1 Translucent MEa 
2 1:2 Fine milky E 
3 1:3 Turbid E 
 
Table 4: Variables in the central composite design of ZRS-NLC 
Independent factors Design level 
Uncoded Coded Uncoded Coded 




0 (Center point) 
1 




0 (Center point) 
1 
 
Table 5: Observed responses in the central composite design of ZRS-NLC 
Formulation code Oil phase S Drug loading (%) mix EE (%) Particle size (nm) 
ZRS1 7.5 56.2132 18.32 70.83 119.62 
ZRS2 7.5 35 15.62 60.85 140.25 
ZRS3 7.5 13.7868 8.92 41.2 165.56 
ZRS4 10 50 21.85 81.34 145.24 
ZRS 5 3.96447 35 22.85 80.52 110.34 
ZRS 6 7.5 35 15.62 60.85 140.25 
ZRS 7 7.5 35 15.62 60.85 140.25 
ZRS8 11.0355 35 19.86 79.25 165.75 
ZRS 9 10 20 12.95 62.25 167 
ZRS 10 7.5 35 15.62 60.85 140.25 
ZRS 11 5 50 25.52 83.62 98.64 
ZRS12 5 20 5.65 36.92 90.28 
ZRS 13 7.5 35 15.62 60.85 140.25 
 
Formulation of ZRS loaded NLC 
The ZRS-NLC consisting of Gelucire 43/01+Capmul MCM (1:1 ratio), 
Labrasol and Transcutol-p were used as surfactants and co-
surfactants in 2:1 ratio was formulated via homogenization (under 
hot) followed by rapid-ultra sonication. The as-prepared, ZRS-NLC 
formulation existed as pale pink colour dispersions.  
Central composite design (table 4-5) was employed towards 
formulating NLCs at 2 factors and 2 levels, with X1 (Oil Phase) and X2 
(Smix
Effect of dependent variables on responses 
) as independent variables, while levels-1 and+1 were chosen 
as low and high, whereas 0 was chosen as the centre point [29]. 
Drug loading and entrapment efficiency 
Effect of Independent variables (under investigation) over drug 
loading and entrapment efficiency (as established by central 
composite design) was presented in table 5. As can be seen, both Oil 
phase and Smix 
Drug loading (R1) =-104.73066+21.79728 Oil phase+5.31367Smix-
0.936676 Oil phase * Smix-1.02546 Oil phase²-0.031745Smix²+ 
0.041270 Oil phase² * Smix+0.003493 Oil phase * Smix² 
displayed a monotonic relationship on entrapment 
efficiency and drug loading (fig. 6). Accordingly, with an increase in 
the concentration of the oil phase, there was a significant increment 
in both responses, thereby reducing the escaping nature of the drug 
into the external phase. Moreover, for optimized formulation 
(ZRS14), entrapment efficiency was found to be 83.53% with a drug 
loading of 25.19%, while the rest of the drug remained free in the 
dispersion media (16.47% of the loaded 25.19%). Thus, 16.47% of 
loaded 25.19% drug (present in dispersion media) was considered 
as the loading dose. While 83.53% of loaded 25.19% (amount of 
drug entrapped in NLC) was considered to be the maintenance dose 
(towards sustained delivery). Further, the desired polynomial 
equations, showed a good fit of responses at different concentrations 
(table 6), thereby supporting the significance of the said model [29]. 
Entrapment efficiency (R2) =-171.85340+31.54012 Oil phase+ 
12.36058 Smix-1.91253 Oil phase* Smix-0.783340 Oil phase²-0.095695 
Smix²+0.063698 Oil phase²* Smix+0.011043 Oil phase* Smix² 
Particle size 
Effect of dependent variables over particle size as depicted in table 5. 
Results suggested that both variables have a progressive impact over 
particle size, while the effect is negative, with Smix as shown in (fig. 6). 
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Further, an increase in concentrations of oil phase leads to the formation 
of aggregates, which in turn increases the particle size from 98.7 to 220.6 
(as shown in table 5). With an increase in the concentration of Smix, 
there is a rapid decrement in particle size. Further, the desired 
polynomial equations, showed a good fit of responses at different 
concentrations (table 6), thereby supporting the significance of the said 
model. Further, for ZRS-14, average particle size was found to be around 
106.4 nm and particle size distribution of optimized formulation was 
depicted in fig 7. The results obtained infers that the selected excipients 
had led to the effective development of desired NLC [29]. 
Particle Size (R3) =+140.25+19.59Oil phase-16.24 Smix-7.53 Oil 
phase * Smix-4.86 Oil phase²-2.59 Smix²+12.89 Oil phase² * 
Smix+11.24Oil phase * Smix² 
 
Table 6: Summary of ANOVA for responses of ZRS-NLC 
Drug loading (%) 
Source Sum of squares df Mean square F value P value Remarks 
Model 354.56 7 50.65 127.91 <0.0001 Significant 
A-Oil Phase 4.47 1 4.47 11.29 0.0201  
B-S 44.18 mix 1 44.18 111.56 0.0001  
AB 30.09 1 30.09 75.97 0.0003  
A² 47.71 1 47.71 120.47 0.0001  
B² 10.85 1 10.85 27.39 0.0034  
A²B 29.94 1 29.94 75.60 0.0003  
AB² 7.72 1 7.72 19.49 0.0069  
Residual 1.98 5 0.3960    
Lack of fit 1.98 1 1.98    
Pure error 0.0000 4 0.0000    
Cor Total 356.54 12     
Entrapment efficiency (%) 
Model 2531.08 7 361.58 245.85 <0.0001 Significant 
A-Oil Phase 0.8064 1 0.8064 0.5483 0.4923  
B-S 438.97 mix 1 438.97 298.47 <0.0001  
AB 190.58 1 190.58 129.58 <0.0001  
A² 568.26 1 568.26 386.38 <0.0001  
B² 58.38 1 58.38 39.69 0.0015  
A²B 71.32 1 71.32 48.50 0.0009  
AB² 77.17 1 77.17 52.47 0.0008  
Residual 7.35 5 1.47    
Lack of fit 7.35 1 7.35    
Pure error 0.0000 4 0.0000    
Cor Total 2538.44 12     
Particle size (nm) 
Model 6855.29 7 979.33 10.84 0.0092 Significant 
A-Oil Phase 1535.13 1 1535.13 16.99 0.0092  
B-S 1055.24 mix 1 1055.24 11.68 0.0189  
AB 226.80 1 226.80 2.51 0.1739  
A² 164.27 1 164.27 1.82 0.2353  
B² 46.55 1 46.55 0.5154 0.5050  
A²B 332.42 1 332.42 3.68 0.1132  
AB² 252.66 1 252.66 2.80 0.1553  
Residual 451.65 5 90.33    
Lack of fit 451.65 1 451.65    
Pure error 0.0000 4 0.0000    
Cor Total 7306.94 12     
 
 
Fig. 6: Three-dimensional response surface plot depicting the impact of the oil phase and Smix on (A) drug loading (B) entrapment 
efficiency and (C) particle size of ZRS-NLCs 
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Fig. 7: Particle size distribution of optimized ZRS-NLC 
 
Optimized formulation  
Optimized formulation (ZRS-14) was obtained by outlining 
responses (required limits) as depicted in table 7. Design expert 
software was used to calculate the required specifications in order 
to formulate desired NLC with combinations of variables. Further, to 
predict the practicability and validity of the obtained model 
obtained, results were overlapped with predicted values [29]. 
  
Table 7: Central composite design enabled ZRS-NLC (optimized formulation) obtained via independent variables and their effects on 
dependent responses 
Value Oil phase (%) Smix Entrapment efficiency (%) (%) Drug loading (%) Particle size (nm) Desirability 
Predicted 5.08 50 83.53 25.51 107  
0.991 Actual 5.1 50 83.49 25.14 106 
% Error 0.02 0 0.04 0.37 1.0 
 
 
Fig. 8: Surface morphology of optimized ZRS-NLC 
 
Surface morphological behaviours of ZRS-NLC 
The SEM photomicrograph of ZRS-NLC (fig. 8) supported that 
particles were spherical in shape and near homogeneous with 
relatively smoother surfaces [20]. 
A comparative account of drug release via in vitro studies 
ZRS-NLC drug release profile was compared with pure ZRS (fig. 9) 
supported that, ZRS-NLC displayed sustained drug release. 
Accordingly, the drug release from pure ZRS was rapid (98.45 over 
8 h) due to initial rapid ZRS release from the NLC surface, in 
contrast to prolonged-release from ZRS-NLC (26.72-80.34% over 
24 h), thereby supporting the sustained delivery of the desired 
drug and hence, the effectiveness of the developed formulation. 
Additionally, the ZRS release pattern from the optimized 
formulation was bi-phasic, associated with an initial short-timed 
(2 h) burst release, followed by a long term (24 h) sustained-
release [21]. 
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Fig. 9: A comparative in vitro drug release profile of pure ZRS and ZRS-NLC; mean±SD, n=3 
 
Cumulative drug permeation measurements via ex-vivo 
diffusion studies 
The data obtained from the permeation studies of pure ZRS and 
optimized ZRS-NLC with sheep nasal mucosa revealed that ZRS-NLC 
had shown significant enhancement in permeation (in contrast to 
pure ZRS). Accordingly, about 77.25±0.19% of ZRS was permeated 
from the optimized NLC formulation, while the same was around 
32.52±0.19% for the pure ZRS (at the end of the same time interval 
(6 h)). Consequently, a steady-state flux of 1.26 μg/cm2/h was 
observed in pure ZRS, whereas, for ZRS-NLC, it was recorded as 5.04 
μg/cm2
Nasal ciliotoxicity studies 
/h. The observed higher flux may be attributed to the 
presence of permeation enhancing surfactants in ZRS-NLC. 
Moreover, the relatively higher lipophilicity of ZRS allows 
significantly better permeation through the nasal mucosa [30]. 
In order to assess the toxicity in the selected excipients employed 
towards the development of ZRS-NLCs ciliotoxicity studies were 
performed. Further, the obtained pictograms had revealed that 
tissue samples treated with the positive control (IPA) had shown a 
severe impact on the sample leading to nasal mucosa damage, 
mucosal shrinkage, and loss of both cilia and epithelial cells. 
However, samples treated with negative control (PBS) had shown 
intact epithelial layers with zero damage to nasal cilia cells. 
However, the nasal mucosa samples treated with optimized ZRS-NLC 
showed no adverse effects (fig. 10). Accordingly, the nasal 
ciliotoxicity studies established that all the excipients involved in the 




Fig. 10: Histopathological sections of sheep nasal mucosa treated with (a) IPA (b) ZRS-NLC and (c) PBS for nasal ciliotoxicity studies 
 
In vitro haemolytic toxicity study 
The formulated ZRS–NLCs upon intranasal administration will enter 
into the systemic circulation where there is a chance of damaging the 
red blood cells. To ascertain the safety of the formulated NLC In vitro 
haemolytic toxicity studies were carried out by formulating a blank 
and drug-loaded NLC, which were incubated by isolated RBCs. Results 
(table 8) suggested that both formulated NLCs were evaluated at a 
concentration range of 0-500 μg/ml, which showed a negligible 
haemolytic effect (0.196-2.857%), which were within the prescribed 
limit (<5%). In order to validate the method Triton X 100, a well-
known haemolytic agent was taken as a positive control [31]. 
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Table 8: In vitro hemolytic study of ZRS-NLC 
Concentration (µg/ml) Percent haemolysis (%)* 
Blank NLC ZRS loaded NLC 
5 0.196±0.02 0.375±0.01 
10 0.395±0.01 0.635±0.05 
25 0.824±0.02 0.952±0.02 
50 1.356±0.03 1.452±0.02 
100 1.789±0.05 1.785±0.03 
250 1.852±0.02 1.898±0.01 
500 2.857±0.05 2.265±0.05 
Absorbance at 100% lysis 0.848±0.01 
Absorbance at 0% lysis 0.297±0.05 
100%-0% 0.551±0.02 
*mean±SD, n = 3 
 
Quantification of drug concentration via in vivo bio-distribution 
studies 
Pharmacokinetic profiles of both plasma and brain (concentration 
against time) for ZRS-NLC delivered through various routes are 
summarized, and representative chromatogram of animal study 
sample at 360th min was depicted in (fig. 11-12). The distribution 
studies revealed that the concentration of ZRS in the brain following 
IN administration was significantly higher at all-time points. 
Nevertheless, when IV route was followed, the concentration of ZRS 
was highest in blood plasma (at all-time points) and lowest in the 
brain. The obtained results supported that when the formulation 
was administered through nasal route, amount of drug distributed 
through systemic circulation was lower when compared with the 
intravenous route, thereby indicating a potential way to deliver the 
desired drug to the brain via nasal route. Further, the obtained blood 
to brain ratio for ZRS administered intranasally was significantly 
higher (1.63±0.31), which supports increased and sustained 
retaining of ZRS at the brain (~ 10 times higher, than IV 
administration). Moreover, lower Tmax 
 
(time taken to attain 
maximum concentration) value of 10 min in the brain, compared 25 
min in plasma suggested that following nasal administration there is 
direct transport from nose to brain. Additionally, the Dug targeting 
efficiency (DTE) and direct transport percentage (DTP) value for 
ZRS-NLC via nasal administration was found to be 476.76±9.53 and 
89.85±7.85, supporting higher targeting efficiency. The lesser nasal 
bioavailability of ZRS in plasma may be attributed to the detail that, 
whenever a drug is administered through nasal route it uses both 
olfactory and trigeminal nerves for its transport, thereby 
successfully bypassing the BBB [32]. 
 
Fig. 11: Mean concentration-time profile after IN and IV administration in both plasma and brain; mean±SD, n=3 
 
 
Fig. 12: Representative chromatogram of the animal study sample of ZRS at 360th min 
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CONCLUSION 
The central composite design was used to formulate desired ZRS-
NLCs, furnishing with oil phase and Smix to obtain NLC with minimum 
particle size and maximum drug loading and entrapment efficiency. 
The present research suggested an enhanced brain targeting of ZRS by 
nasal route. Moreover, the observed high DTE and DTP values for ZRS-
NLC suggested that formulated ZRS-NLC had by-passed BBB. The 
research also supports that optimized ZRS-NLC can permeate through 
nasal mucosa without any structural damages. To sum up, the present 
findings support that ZRS-NLC could be a promising alternative 
approach for brain targeting via nasal route.  
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